CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the CTAD 2024 conference. Read why ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

Viking (VKTX) stock fell 13% Monday afternoon after jumping 9% earlier in the day amid concerns the company might face production problems for its obesity drug candidate VK2735.

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Madrigal Pharmaceuticals ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Celebrations may be in order for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The ...

Hedge funds increased their equity-risk exposure in August. Here are the stocks they swung from long to short positions, Jefferies says.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report), Organon ...